Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke

CNS Drugs. 2015;29(10):811-8. doi: 10.1007/s40263-015-0280-9.


Given that alteplase has been the only approved thrombolytic agent for acute ischemic stroke for almost two decades, there has been intense interest in more potent and safer agents over the last few years. Tenecteplase is a bioengineered mutation of alteplase with advantageous pharmacodynamics and pharmacokinetics. The superiority of tenecteplase over alteplase has been proven by in vitro and animal studies, and it was approved for use in myocardial infarction more than a decade ago. In patients with acute ischemic stroke, tenecteplase has shown promise in randomized phase II trials and the drug is currently being tested in four phase III clinical trials that will start delivering definite results in the near future: NOR-TEST (NCT01949948), TASTE (ACTRN12613000243718), TEMPO-2 (NCT02398656), and TALISMAN (NCT02180204).

Publication types

  • Review

MeSH terms

  • Animals
  • Brain Ischemia / drug therapy*
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Disease Management
  • Humans
  • Neuroprotective Agents / chemistry
  • Neuroprotective Agents / pharmacokinetics
  • Neuroprotective Agents / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Stroke / drug therapy*
  • Tenecteplase
  • Tissue Plasminogen Activator / chemistry
  • Tissue Plasminogen Activator / pharmacokinetics
  • Tissue Plasminogen Activator / therapeutic use*


  • Neuroprotective Agents
  • Tissue Plasminogen Activator
  • Tenecteplase

Associated data

  • ANZCTR/ACTRN12613000243718